155 related articles for article (PubMed ID: 14686964)
1. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
Skurk T; Lee YM; Nicuta-Rölfs TO; Haastert B; Wirth A; Hauner H
Diabetes Obes Metab; 2004 Jan; 6(1):56-62. PubMed ID: 14686964
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
Hirschl MM; Bur A; Woisetschlaeger C; Derhaschnig U; Laggner AN
J Clin Hypertens (Greenwich); 2007 Jun; 9(6):430-5. PubMed ID: 17541328
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.
Seljeflot I; Moan A; Kjeldsen S; Sandvik E; Arnesen H
Hypertension; 1996 Jun; 27(6):1299-304. PubMed ID: 8641739
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
7. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
8. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
9. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
10. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
17. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Melian EB; Jarvis B
Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
[TBL] [Abstract][Full Text] [Related]
18. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R
J Hum Hypertens; 2004 Oct; 18(10):687-91. PubMed ID: 15071488
[TBL] [Abstract][Full Text] [Related]
19. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
Sakata K; Pawlak R; Urano T; Takada A
Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
